Pharming Group N.V. reported a 19% revenue increase to $245.3 million for 2023, primarily driven by $227.1 million sales of RUCONEST® and $18.2 million from the new Joenja® product. The full-year loss was $10.1 million, with cash reserves rising to $215 million as of December 31, 2023.